Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua T Kantrowitz

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
Expert Opinion on Pharmacotherapy|June 16, 2021
How do we address treating the negative symptoms of schizophrenia pharmacologically?Joshua T Kantrowitz
CNS Drugs|August 13, 2020
Targeting Serotonin 5-HT<sub>2A</sub> Receptors to Better Treat Schizophrenia: Rationale and Current ApproachesJoshua T Kantrowitz
Expert Opinion on Pharmacotherapy|August 23, 2021
Additional perspective on cariprazine and negative symptomsJoshua T Kantrowitz
JAMA Psychiatry|January 9, 2020
The Potential Role of Lumateperone-Something Borrowed? Something New?Joshua T Kantrowitz
CNS Drugs|April 12, 2017
Managing Negative Symptoms of Schizophrenia: How Far Have We Come?Joshua T Kantrowitz
Schizophrenia Research|February 21, 2018
N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophreniaJoshua T Kantrowitz
CNS Drugs|October 16, 2021
Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future DirectionsJoshua T Kantrowitz
Expert Opinion on Drug Safety|November 6, 2008
Olanzapine: review of safety 2008Joshua T Kantrowitz, Leslie Citrome
Biological Psychiatry|September 1, 2024
Finding the Right Dose: NMDA Receptor-Modulating Treatments for Cognitive and Plasticity Deficits in Schizophrenia and the Role of Pharmacodynamic Target EngagementPejman Sehatpour, Joshua T Kantrowitz
CNS Drugs|January 12, 2025
Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment LandscapePreetika Govil, Joshua T Kantrowitz
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Expert Opinion on Pharmacotherapy|June 16, 2021
How do we address treating the negative symptoms of schizophrenia pharmacologically?Joshua T Kantrowitz
CNS Drugs|August 13, 2020
Targeting Serotonin 5-HT<sub>2A</sub> Receptors to Better Treat Schizophrenia: Rationale and Current ApproachesJoshua T Kantrowitz
Expert Opinion on Pharmacotherapy|August 23, 2021
Additional perspective on cariprazine and negative symptomsJoshua T Kantrowitz
JAMA Psychiatry|January 9, 2020
The Potential Role of Lumateperone-Something Borrowed? Something New?Joshua T Kantrowitz
CNS Drugs|April 12, 2017
Managing Negative Symptoms of Schizophrenia: How Far Have We Come?Joshua T Kantrowitz
Schizophrenia Research|February 21, 2018
N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophreniaJoshua T Kantrowitz
CNS Drugs|October 16, 2021
Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future DirectionsJoshua T Kantrowitz
Expert Opinion on Drug Safety|November 6, 2008
Olanzapine: review of safety 2008Joshua T Kantrowitz, Leslie Citrome
Biological Psychiatry|September 1, 2024
Finding the Right Dose: NMDA Receptor-Modulating Treatments for Cognitive and Plasticity Deficits in Schizophrenia and the Role of Pharmacodynamic Target EngagementPejman Sehatpour, Joshua T Kantrowitz
CNS Drugs|January 12, 2025
Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment LandscapePreetika Govil, Joshua T Kantrowitz
Pageof 9